Linaclotide vs Larazotide Acetate
Both are oral peptides that act locally in the gut. Linaclotide increases fluid secretion through guanylate cyclase-C and is approved for constipation; larazotide targets permeability and remains investigational.
Linaclotide
A 14-amino-acid gut-acting peptide that activates guanylate cyclase-C on intestinal cells — one of the few oral peptide drugs.
BEST STUDIED FOR
Repair & immune
Read the cited profile →
Larazotide Acetate
An 8-amino-acid tight-junction regulator designed to reduce intestinal permeability, studied mainly in coeliac disease.
BEST STUDIED FOR
Repair & immune
Read the cited profile →
SIDE BY SIDE
| Linaclotide | Larazotide Acetate | |
|---|---|---|
| The key difference | Guanylate cyclase-C agonist — gut secretion | Tight-junction regulator — gut permeability |
| Class | Repair & immune | Repair & immune |
| Mechanism | Linaclotide activates guanylate cyclase-C on the luminal surface of intestinal epithelium, raising cyclic GMP. | Larazotide is proposed to antagonise zonulin-mediated opening of epithelial tight junctions, limiting paracellular passage of gliadin fragments in the gut. |
| Status | Approved in the US and other markets for chronic idiopathic constipation and constipation-predominant IBS in adults, and for functional constipation in children aged 6–17. | Reached phase 3 in coeliac disease, which was discontinued; remains a reference tight-junction research compound, including in colitis and arthritis models. |
| Reported safety signals | In the paediatric phase 3 trial the most frequent treatment-related adverse event was diarrhoea (4% versus 1% on placebo). | Clinical trials reported it as well tolerated; efficacy, not safety, ended the phase 3 programme. |
| A key study | A phase 3 randomised placebo-controlled trial in 328 children aged 6–17 found linaclotide efficacious and well tolerated for functional constipation. (Lancet Gastroenterol Hepatol 2024, PMID 38211604) | Reviews tight-junction regulation in coeliac disease with a focus on larazotide. (Ther Adv Gastroenterol 2016, PMID 26770266) |
WHEN TO RESEARCH WHICH
Linaclotide for secretion and visceral-pain research; larazotide for barrier research. Both are discussed here strictly as research compounds; nothing on this page is medical advice or a dosing guide.
REFERENCES (PUBMED)
- [Linaclotide] Efficacy and safety of linaclotide in treating functional constipation in paediatric patients: a randomised, double-blind, placebo-controlled, multicentre, phase 3 trial — Lancet Gastroenterol Hepatol 2024. PMID 38211604
- [Linaclotide] Guanylate cyclase-C agonists as peripherally acting treatments of chronic visceral pain — Trends Pharmacol Sci 2022. PMID 34865885
- [Linaclotide] Comparative profiles of lubiprostone, linaclotide, and elobixibat for chronic constipation: a systematic literature review with meta-analysis and number needed to treat/harm — BMC Gastroenterol 2024. PMID 38166671
- [Larazotide Acetate] The potential utility of tight junction regulation in celiac disease: focus on larazotide acetate — Ther Adv Gastroenterol 2016. PMID 26770266
- [Larazotide Acetate] Targeting zonulin and intestinal epithelial barrier function to prevent onset of arthritis — Nat Commun 2020. PMID 32332732
- [Larazotide Acetate] Antibacterial hyaluronic acid hydrogel with sustained release of larazotide as effective colitis treatment — J Control Release 2025. PMID 40915363
FREQUENTLY ASKED
What is the difference between Linaclotide and Larazotide Acetate?
Both are oral peptides that act locally in the gut. Linaclotide increases fluid secretion through guanylate cyclase-C and is approved for constipation; larazotide targets permeability and remains investigational.
What is the regulatory status of Linaclotide and Larazotide Acetate?
Linaclotide: Approved in the US and other markets for chronic idiopathic constipation and constipation-predominant IBS in adults, and for functional constipation in children aged 6–17. Larazotide Acetate: Reached phase 3 in coeliac disease, which was discontinued; remains a reference tight-junction research compound, including in colitis and arthritis models.
What safety signals have been reported?
Linaclotide: In the paediatric phase 3 trial the most frequent treatment-related adverse event was diarrhoea (4% versus 1% on placebo). Larazotide Acetate: Clinical trials reported it as well tolerated; efficacy, not safety, ended the phase 3 programme.
Which studies is this comparison based on?
For Linaclotide: “Efficacy and safety of linaclotide in treating functional constipation in paediatric patients: a randomised, double-blind, placebo-controlled, multicentre, phase 3 trial” (PMID 38211604); “Guanylate cyclase-C agonists as peripherally acting treatments of chronic visceral pain” (PMID 34865885); “Comparative profiles of lubiprostone, linaclotide, and elobixibat for chronic constipation: a systematic literature review with meta-analysis and number needed to treat/harm” (PMID 38166671). For Larazotide Acetate: “The potential utility of tight junction regulation in celiac disease: focus on larazotide acetate” (PMID 26770266); “Targeting zonulin and intestinal epithelial barrier function to prevent onset of arthritis” (PMID 32332732); “Antibacterial hyaluronic acid hydrogel with sustained release of larazotide as effective colitis treatment” (PMID 40915363).
MORE COMPARISONS
All products supplied for research purposes only. Not for human consumption.
In stock · ships from South Africa
In stock now
Supplied for laboratory research only · not for human use